| Trial | Sponsor | Phase | Status | Primary completion |
|---|
| A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)NCT05269355 | PTC Therapeutics | Phase 2, Phase 3 | Terminated | 2024-06-17Actual |
| Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe GastroparesisNCT05270460 | Processa Pharmaceuticals | Phase 2 | Completed | 2022-09-29Actual |
| An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 StudyNCT05271370 | CytoDyn, Inc. | Phase 2, Phase 3 | Terminated | 2022-06-20Actual |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)NCT05271552 | BioXcel Therapeutics Inc | Phase 3 | Completed | 2023-04-21Actual |
| A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckNCT05271604 | BioAtla, Inc. | Phase 2 | Completed | 2025-09-22Actual |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With FibromyalgiaNCT05273749 | Tonix Pharmaceuticals, Inc. | Phase 3 | Completed | 2023-11-14Actual |
| A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung CancerNCT05275673 | Faeth Therapeutics | Phase 2 | Terminated | 2023-01-24Actual |
| An Efficacy, and Safety Study Of BXCL501 For The Treatment Of Agitation Associated With DementiaNCT05276830 | BioXcel Therapeutics Inc | Phase 2 | Terminated | 2022-04-01Actual |
| ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)NCT05279417 | ACRS | Phase 2 | Completed | 2023-09-05Actual |
| Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable TumorsNCT05280314 | IO Biotech | Phase 2 | Recruiting | 2025-04-30Estimated |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)NCT05281471 | Genelux Corporation | Phase 3 | Recruiting | 2026-12Estimated |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB1 Antagonist ANEB-001 in a THC Challenge TestNCT05282797 | Anebulo Pharmaceuticals | Phase 2 | Completed | 2023-08-26Actual |
| Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic SeizuresNCT05288283 | Jazz Pharmaceuticals | Phase 3 | Terminated | 2023-09-28Actual |
| A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.NCT05288504 | AVTX | Phase 2 | Completed | 2023-05-11Actual |
| Voclosporin in Adolescent and Pediatric Subjects With Lupus NephritisNCT05288855 | AUPH | Phase 3 | Terminated | 2025-07-03Actual |
| Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)NCT05291091 | EWTX | Phase 2 | Completed | 2026-09-07Actual |
| Efficacy and Safety of ALT-801 in the Treatment of ObesityNCT05295875 | ALT | Phase 2 | Completed | 2023-09-28Actual |
| A Randomized, Double-Blind Study to Assess the Safety, Efficacy and Tolerability of Oral DFD-29 Capsules for the Treatment of Rosacea.NCT05296629 | Journey Medical Corporation | Phase 3 | Completed | 2023-06-30Actual |
| Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older AdultsNCT05297578 | PCVX | Phase 2 | Completed | 2023-02-15Actual |
| A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid MalignanciesNCT05301517 | Kyntra Bio | Phase 3 | Completed | 2023-04-03Actual |
| Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064 | Alkermes, Inc. | Phase 3 | Recruiting | 2027-12Estimated |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)NCT05303519 | NUVB | Phase 3 | Recruiting | 2028-12-01Estimated |
| A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574 | Vor Biopharma | Phase 3 | Terminated | 2025-01-06Actual |
| Study of Bitopertin to Evaluate the Safety, Tolerability, Efficacy, and PPIX Concentrations in Participants With EPPNCT05308472 | IRON | Phase 2 | Completed | 2024-02-20Actual |
| The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress DisorderNCT05312151 | COMPASS Pathways | Phase 2 | Completed | 2024-02-12Actual |
| Long-term Extension Study of Setrusumab in Adults With Type I, III, or IV Osteogenesis ImperfectaNCT05312697 | RARE | Phase 2 | Terminated | 2022-07-07Actual |
| A Study to Assess the Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of ION904 in Participants With Uncontrolled HypertensionNCT05314439 | IONS | Phase 2 | Completed | 2023-01-31Actual |
| Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular CarcinomaNCT05317819 | Polaris Group | Phase 3 | Recruiting | 2028-09Estimated |
| A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive ImpairmentNCT05318937 | SUPN | Phase 2 | Completed | 2024-01-17Actual |
| A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of InflammationNCT05318976 | INMB | Phase 2 | Completed | 2025-05-12Actual |
Trial details
- Registry ID
- NCT05269355
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05270460
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05271370
- Phase
- Phase 2, Phase 3
Trial details
- Registry ID
- NCT05271552
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05271604
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05273749
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05275673
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05276830
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05279417
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05280314
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05281471
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05282797
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05288283
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05288504
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05288855
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05291091
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05295875
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05296629
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05297578
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05301517
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05303064
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05303519
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05306574
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05308472
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05312151
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05312697
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05314439
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05317819
- Phase
- Phase 3
Trial details
- Registry ID
- NCT05318937
- Phase
- Phase 2
Trial details
- Registry ID
- NCT05318976
- Phase
- Phase 2
Primary completion marks the end of data collection for the main study measures, not a results publication date.